Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Blood (2023) 142 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2023-181233

Published: 2023

Journal Articles

Peripherally Inserted Central Catheter Safety and Efficacy in Acute Myeloid Leukemia: A Monocentric Experience from the Hematology of Cagliari

Daniele Derudas, Sabrina Chiriu, Claudio Romani, Federica Pilo, Martina Pettinau, Giuseppe Longhitano, Daniela Ibba, Loredana Aracu, Giorgio La Nasa

Blood (2023) 142 (Supplement 1): 7289.

https://doi.org/10.1182/blood-2023-187138

Published: 2023

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)

Blood (2023) 142 (Supplement 1): 205.

https://doi.org/10.1182/blood-2023-177673

Published: 2023

Journal Articles

Isatuximab-Based Regimens As Salvage Therapy for Patients with Multiple Myeloma: Sardinian, Multicenter, Retrospective Clinical Practice Experience with 27 Cases Outside of Controlled Clinical Trials

Daniele Derudas, Luigi Podda, Angelo D. Palmas, Rita Floris, Annamaria Liguori, Cristina Depau, Alessandro Bianchi, Claudio Fozza, Giorgio La Nasa

Blood (2023) 142 (Supplement 1): 6658.

https://doi.org/10.1182/blood-2023-190412

Published: 2023

Journal Articles

Peripherally Inserted Central Catheter Safety and Efficacy in Acute Lymphoblastic Leukemias: A 16-Years Monocentric Experience

Daniele Derudas, Sabrina Chiriu, Claudio Romani, Federica Pilo, Martina Pettinau, Giuseppe Longhitano, Daniela Ibba, Loredana Aracu, Giorgio La Nasa

Blood (2023) 142 (Supplement 1): 7255.

https://doi.org/10.1182/blood-2023-187272

Published: 2023

Journal Articles

Thromboembolic Complications PICC-Related in Adult Patients Affected By Hematologic Diseases: A 13-Years Monocentric Experience

Daniele Derudas, Stefania Massidda, Maria Pina Simula, Daniela Dessì, Sara Veronica Usai, Claudio Romani, Giuseppe Longhitano, Daniela Ibba, Loredana Aracu, Giorgio La Nasa

Blood (2022) 140 (Supplement 1): 11306–11307.

https://doi.org/10.1182/blood-2022-166952

Published: 2022

Journal Articles

PICC Insertion and Management in Hodgkin and NON-Hodgkin Lymphomas: A 13-YEARS Monocentric Experience

Daniele Derudas, Maria Pina Simula, Stefania Massidda, Daniela Dessì, Sara Veronica Usai, Giuseppe Longhitano, Daniela Ibba, Loredana Aracu, Giorgio La Nasa

Blood (2022) 140 (Supplement 1): 5077–5078.

https://doi.org/10.1182/blood-2022-167489

Published: 2022

Journal Articles

Clonal Hematopoiesis: Exploiting Molecular Landscape of Multiple Myeloma Patients for Choosing the Most Appropriate Therapeutic Strategy

Elisa Gelli, Antonella Laudisi, Claudia Martinuzzi, Debora Soncini, Pamela Becherini, Fabio Guolo, Concetta Conticello, Daniele Derudas, Francesco Di Raimondo, Antonia Cagnetta, Domenico Coviello, Roberto Massimo Lemoli, Michele Cea

Blood (2022) 140 (Supplement 1): 7064–7065.

https://doi.org/10.1182/blood-2022-169263

Published: 2022

Journal Articles

Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study

Massimo Offidani, Michele Cavo, Daniele Derudas, Francesco Di Raimondo, Antonio Cuneo, Luca Baldini, Roberta Della Pepa, Maurizio Musso, Mario Boccadoro, Pellegrino Musto, Maria Teresa Petrucci, Angelo Belotti

Blood (2022) 140 (Supplement 1): 7222–7223.

https://doi.org/10.1182/blood-2022-166399

Published: 2022

Journal Articles

The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 115.

https://doi.org/10.1182/blood-2021-145977

Published: 2021

Journal Articles

On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877)

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-136316

Published: 2020

Journal Articles

Risk of Early Severe Infections in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Agents: A Pooled Analysis

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-136302

Published: 2020

Journal Articles

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Alessandra Pompa, Concetta Conticello, MD, Diana Giannarelli, PhD, Loredana Pettine, MD, Laura Paris, MD, Lucia Tognazzi, Magda Marcatti, MD, Elisabetta Antonioli, MD, Francesca Fioritoni, MD, Angela Bonalumi, MD, Silvia Mangiacavalli, Paola Bertazzoni, Iolanda Donatella Vincelli, MD, Daniele Derudas, MD, Agostina Siniscalchi, Sara Pezzatti, MD, Renato Zambello, Annalisa Citro, MD, Angelo Belotti, Alessandra Lombardo, MD, Federico Vozella, MD, Adelina Sementa, MD, Ugo Consoli, MD, Alfredo Molteni, MD, Niccolò Frungillo, MD, Massimo Gentile, MD, Gabriele Buda, MD PhD, Sara Aquino, Salvatore Palmieri, Velia Bongarzoni, MD, Alessandro Inzoli, MD, Valeria Ferla, MD, Francesca Gaia Rossi, MD, Valerio Leotta, MD, Alessandra Romano, MD PhD, Federica Elia, MD, Vittorio Del Fabro, MD, Guido Montanaro, MD, Francesca Cavallaro, MD, Monica Galli, Luca Baldini, MD PhD

Blood (2019) 134 (Supplement_1): 5555.

https://doi.org/10.1182/blood-2019-125098

Published: 2019

Journal Articles

Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes

Blood (2018) 132 (Supplement 1): 125.

https://doi.org/10.1182/blood-2018-99-116716

Published: 2018

Journal Articles

PICC Insertion and Management in Hodgkin Lymphoma Patients: A 10-YEARS Monocentric Prospective Study

Daniele Derudas, MD, Stefania Massidda, Giuseppe Longhitano, Daniela Ibba, Giovanni Caocci, MD, Emanuele Angelucci, MD, Giorgio La Nasa, MD

Blood (2018) 132 (Supplement 1): 5844.

https://doi.org/10.1182/blood-2018-99-115330

Published: 2018

Journal Articles

Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Blood (2018) 132 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2018-99-115340

Published: 2018

Journal Articles

Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated Analysis of EMN01 Phase III Study

Blood (2017) 130 (Supplement 1): 901.

https://doi.org/10.1182/blood.V130.Suppl_1.901.901

Published: 2017

Journal Articles

Computed Tomography-Guided SCREW Fixation PLUS Cementoplasty in Myeloma Patients

Daniele Derudas, MD, Claudio Pusceddu, MD, Federica Pilo, MD, Nicola Ballicu, MD, Luca Melis, MD, Emanuele Angelucci, MD

Blood (2016) 128 (22): 5971.

https://doi.org/10.1182/blood.V128.22.5971.5971

Published: 2016

Journal Articles

Once Daily Intravenous Busulphan Plus Fludarabine As New Reduced Toxicity Myeloablative Conditioning for Acute Myeloid Leukemia and MDS Allogeneic Transplantation

Donatella Baronciani, MD, Cristina Depau, MD, Clara Targhetta, MD, Anna Angela Di Tucci, MD, Daniele Derudas, MD, Fabio Culurgioni, PhD, Donatella Pulisci, PhD, Igor Tandurella, PhD, Emanuele Angelucci, MD

Blood (2014) 124 (21): 5861.

https://doi.org/10.1182/blood.V124.21.5861.5861

Published: 2014

Journal Articles

Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

Annamaria Brioli, MD, Annalisa Pezzi, Statistician, Daniele Derudas, MD, Maria Concetta Petti, MD, Beatrice Anna Zannetti, MD, Felicetto Ferrara, MD, Serena Rocchi, MD, Francesco Nobile, MD, Anna Baraldi, MD, Pellegrino Musto, MD, Francesco Lanza, MD, Katia Mancuso, MD, Letizia Canepa, MD, Lucio Catalano, MD, Antonio Lazzaro, MD, Graziella Pinotti, MD, Mario Boccadoro, MD, Michele Cavo, MD

Blood (2014) 124 (21): 1182.

https://doi.org/10.1182/blood.V124.21.1182.1182

Published: 2014

NARROW

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Peripherally Inserted Central Catheter Safety and Efficacy in Acute Myeloid Leukemia: A Monocentric Experience from the Hematology of Cagliari

Carfilzomib-Lenalidomide-Dexamethasone (KRd) Vs. Lenalidomide-Dexamethasone (Rd) in Newly Diagnosed Fit or Intermediate-Fit Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation (Phase III EMN20 Trial): Analysis of Sustained Undetectable Minimal Residual Disease (MRD)

Isatuximab-Based Regimens As Salvage Therapy for Patients with Multiple Myeloma: Sardinian, Multicenter, Retrospective Clinical Practice Experience with 27 Cases Outside of Controlled Clinical Trials

Peripherally Inserted Central Catheter Safety and Efficacy in Acute Lymphoblastic Leukemias: A 16-Years Monocentric Experience

Thromboembolic Complications PICC-Related in Adult Patients Affected By Hematologic Diseases: A 13-Years Monocentric Experience

PICC Insertion and Management in Hodgkin and NON-Hodgkin Lymphomas: A 13-YEARS Monocentric Experience

Clonal Hematopoiesis: Exploiting Molecular Landscape of Multiple Myeloma Patients for Choosing the Most Appropriate Therapeutic Strategy

Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study

The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma

On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877)

Risk of Early Severe Infections in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Agents: A Pooled Analysis

Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes

PICC Insertion and Management in Hodgkin Lymphoma Patients: A 10-YEARS Monocentric Prospective Study

Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials

Computed Tomography-Guided SCREW Fixation PLUS Cementoplasty in Myeloma Patients

Once Daily Intravenous Busulphan Plus Fludarabine As New Reduced Toxicity Myeloablative Conditioning for Acute Myeloid Leukemia and MDS Allogeneic Transplantation

Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only